Type 2 diabetes mellitus and fracture risk

被引:173
作者
Dede, Anastasia D. [1 ]
Tournis, Symeon [2 ]
Dontas, Ismene [2 ]
Trovas, George [2 ]
机构
[1] Hippokrateion Hosp, Dept Endocrinol & Metab, Athens 11527, Greece
[2] Univ Athens, KAT Hosp, Lab Res Musculoskeletal Syst Theodoros Garofalidi, Athens, Greece
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2014年 / 63卷 / 12期
关键词
Diabetes; Bone fragility; Fracture healing; Advanced glycation end-products; Collagen cross-linking; BONE-MINERAL DENSITY; GLYCATION END-PRODUCTS; POSTMENOPAUSAL WOMEN; NONENZYMATIC GLYCATION; VERTEBRAL FRACTURES; OLDER-ADULTS; IN-VIVO; OSTEOBLASTIC DIFFERENTIATION; BIOMECHANICAL PROPERTIES; OSTEOPOROTIC FRACTURES;
D O I
10.1016/j.metabol.2014.09.002
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Increased fracture risk, traditionally associated with type 1 diabetes, has lately been of great concern in patients with type 2 diabetes. A variable increase in fracture risk has been reported, ranging from 20% to 3-fold, depending on skeletal site, diabetes duration and study design. Longer disease duration, the presence of diabetic complications, inadequate glycemic control, insulin use and increased risk for falls are all reported to increase fracture risk. Patients with type 2 diabetes display a unique skeletal phenotype with either normal or more frequently increased, bone mineral density and impaired structural and geometric properties. Recently, alterations in bone material properties seem to be the predominant defect leading to increased bone fragility. Accumulation of advanced glycation end-products and changes in collagen cross-linking along with suppression of bone turnover seem to be significant factors impairing bone strength. FRAX score has been reported to underestimate fracture risk and lumbar spine BMD is inadequate in predicting vertebral fractures. Anti-diabetic medications, apart from thiazolidinediones, appear to be safe for the skeleton, although more data are needed. Optimal strategies to reduce skeletal fragility in type 2 diabetic patients are yet to be determined. (C)2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:1480 / 1490
页数:11
相关论文
共 105 条
[1]
Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways [J].
Alikhani, Mani ;
Alikhani, Zoubin ;
Boyd, Coy ;
MacLellan, Christine M. ;
Raptis, Markos ;
Liu, Rongkun ;
Pischon, Nicole ;
Trackman, Philip C. ;
Gerstenfeld, Louis ;
Graves, Dana T. .
BONE, 2007, 40 (02) :345-353
[2]
[Anonymous], 2013, IDF DIABETES ATLAS
[3]
Effects of reactive oxygen species (ROS) on antioxidant system and osteoblastic differentiation in MC3T3-E1 cells [J].
Arai, Masato ;
Shibata, Yasuko ;
Pugdee, Kamolparn ;
Abiko, Yoshimitsu ;
Ogata, Yorimasa .
IUBMB LIFE, 2007, 59 (01) :27-33
[4]
Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes [J].
Ardawi, Mohammed-Salleh M. ;
Akhbar, Daad H. ;
AlShaikh, Abdulrahman ;
Ahmed, Maimoona M. ;
Qari, Mohammed H. ;
Rouzi, Abdulrahim A. ;
Ali, Ahmed Y. ;
Abdulrafee, Adel A. ;
Saeda, Mamdouh Y. .
BONE, 2013, 56 (02) :355-362
[5]
Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes [J].
Bilik, Dori ;
McEwen, Laura N. ;
Brown, Morton B. ;
Pomeroy, Nathan E. ;
Kim, Catherine ;
Asao, Keiko ;
Crosson, Jesse C. ;
Duru, O. Kenrik ;
Ferrara, Assiamira ;
Hsiao, Victoria C. ;
Karter, Andrew J. ;
Lee, Pearl G. ;
Marrero, David G. ;
Selby, Joe V. ;
Subramanian, Usha ;
Herman, William H. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (10) :4560-4565
[6]
Osteoblast-derived cells express functional glucose dependent insulinotropic peptide receptors [J].
Bollag, RJ ;
Zhong, Q ;
Phillips, P ;
Min, L ;
Zhong, L ;
Cameron, R ;
Mulloy, AL ;
Rasmussen, H ;
Qin, F ;
Ding, KH ;
Isales, CM .
ENDOCRINOLOGY, 2000, 141 (03) :1228-1235
[7]
Risk of fracture in women with type 2 diabetes: The Women's Health Initiative Observational Study [J].
Bonds, Denise E. ;
Larson, Joseph C. ;
Schwartz, Ann V. ;
Strotmeyer, Elsa S. ;
Robbins, John ;
Rodriguez, Beatriz L. ;
Johnson, Karen C. ;
Margolis, Karen L. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (09) :3404-3410
[8]
A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients [J].
Borges, J. L. C. ;
Bilezikian, J. P. ;
Jones-Leone, A. R. ;
Acusta, A. P. ;
Ambery, P. D. ;
Nino, A. J. ;
Grosse, M. ;
Fitzpatrick, L. A. ;
Cobitz, A. R. .
DIABETES OBESITY & METABOLISM, 2011, 13 (11) :1036-1046
[9]
The effect of pramlintide (Amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus [J].
Borm, AK ;
Klevesath, MS ;
Borcea, V ;
Kasperk, C ;
Seibel, MJ ;
Wahl, P ;
Ziegler, R ;
Nawroth, PP .
HORMONE AND METABOLIC RESEARCH, 1999, 31 (08) :472-475
[10]
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes [J].
Bunck, M. C. ;
Eliasson, B. ;
Corner, A. ;
Heine, R. J. ;
Shaginian, R. M. ;
Taskinen, M. -R. ;
Yki-Jaervinen, H. ;
Smith, U. ;
Diamant, M. .
DIABETES OBESITY & METABOLISM, 2011, 13 (04) :374-377